CARsgen Therapeutics to Raise HK$462 Million via Top-Up Placement

MT Newswires Live05-15

CARsgen Therapeutics (HKG:2171) is set to raise about HK$462 million in net proceeds through a top-up placement, according to a Friday Hong Kong bourse filing.

YIJIE Biotech Holding, a substantial shareholder, is selling 23.7 million existing shares to independent investors.

In turn, the company will issue the same number of new shares to YIJIE Biotech at the same price under its general mandate.

The placing price is set at HK$19.84 per share, representing a 9.5% discount to the last close and a 12.9% discount to the five-day average.

Net proceeds will be used for global clinical development of innovative drugs, equipment, and facility expenses for research and manufacturing, and working capital and general corporate purposes, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment